An international group of researchers has discovered a new tool that can reveal a key pathology of Parkinson’s disease in brain and body cells.
The identification of the new biomarker, known as abnormal alpha-synuclein, opens a new chapter for research, according to The Michael J. Fox Foundation for Parkinson’s Research.
The foundation led the coalition and its landmark clinical study, Parkinson’s Progression Markers Initiative (PPMI).
